LFB Announces that the European Medicines Agency (EMA) Has Accepted for Filing the Marketing Authorization Application for eptacog beta (activated), a Recombinant Coagulation Factor VIIa
LFB today announced that the European Medicines Agency (EMA), the European regulatory authority, has accepted for filing the Marketing Authorization Application for eptacog beta, a recombinant coagulation Factor VIIa (rFVIIa).
The application includes data from three prospective phase 3 clinical trials (PERSEPT1, PERSEPT2, and PERSEPT3) assessing the efficacy and safety of eptacog beta in the treatment of bleeding episodes in children and adults with congenital haemophilia A or B with inhibitors and for the prevention of bleeding in those patients undergoing surgery or invasive procedures. The final outcome from the EMA review is expected by mid-2022.
This announcement comes less than a year after the approval in April 2020 by the United States Food and Drug Administration (FDA) of LFB’s Biologics License Application (BLA) for the coagulation factor VIIa (recombinant)-jncw (eptacog beta), under the name SEVENFACT®, for the treatment and control of bleeding episodes occurring in adults and adolescents (12 years of age and older) with haemophilia A or B with inhibitors. A sBLA efficacy supplement is currently under FDA review, with a regulatory outcome expected by mid-2021. An exclusive license for the commercialization of SEVENFACT® in the USA has been granted to HEMA Biologics, a joint venture between LFB and US WorldMeds.
In parallel, LFB announces the online publication of the exploratory in vitro study of eptacog beta in combination with emicizumab in the journal Haemophilia.1 The combination of eptacog beta with emicizumab results in a concentration-dependent increase in thrombin generation in haemophilia plasma that remains below that of normal non-haemophilic plasma.
These exploratory study results provide in vitro data supporting the concept of eptacog beta use for the treatment of breakthrough bleeding in haemophilia patients treated with emicizumab. A clinical study is planned in the first quarter 2021 to further evaluate the use of SEVENFACT® in this patient population.2 The recommendation from the Medical and Scientific Advisory Council (MASAC) of the National Hemophilia Foundation in the USA supports the use of SEVENFACT® for the treatment of breakthrough bleeding in patients using emicizumab prophylaxis.3
About the exploratory in vitro study
The aim of this study was to determine the in vitro procoagulant activity of eptacog beta and emicizumab (alone and in combination) utilizing a thrombin generation assay with haemophilia A plasma with and without inhibitors.
A significant increase in peak thrombin, endogenous thrombin potential and velocity was observed for combinations of eptacog beta (0, 1, 2 or 5 µg/mL) with emicizumab (0, 50 or 100 µg/mL) in haemophilia A and haemophilia A plasma with inhibitors; the effect remained below that observed in normal, non-haemophilic plasma.
This study was sponsored by LFB. More details can be found in the study manuscript available at https://onlinelibrary.wiley.com/doi/full/10.1111/hae.14253
LFB is a biopharmaceutical group that develops, manufactures, and markets plasma-derived medicinal products and recombinant proteins for the treatment of patients with serious and often rare diseases.
Created in France in 1994, LFB is today one of the leading European companies providing plasma-derived and recombinant medicinal products to healthcare professionals. Its mission is to offer patients new treatment options for unmet needs in three major therapeutic areas: immunology, haemostasis and intensive care.
LFB’s current market portfolio includes 15 biomedicinal products sold in over 30 countries.
Please visit www.lfb-group.com for additional information.
About HEMA Biologics, LLC
HEMA Biologics is a biopharmaceutical company, located in Louisville, KY. HEMA Biologics has commercialization and distribution rights for SEVENFACT® in the USA and Canada. HEMA Biologics takes pride in the heritage of LFB, the developer and manufacturer of SEVENFACT®.
The company is dedicated to meeting the needs of patients living with rare bleeding disorders, supporting the community that cares for them, and bringing meaningful products and services to the marketplace to help improve their daily lives.
Please visitwww.hemabio.comfor additional information.
1Grandoni J, Duretz V, Bonzo D, et al. Exploratory in vitro evaluation of thrombin generation of eptacog beta (recombinant human FVIIa) and emicizumab in congenital haemophilia A plasma. Haemophilia 2021 Feb; https://onlinelibrary.wiley.com/doi/full/10.1111/hae.14253Online ahead of print.
2ATHN16 study coordinated by the American Thrombosis and Hemostasis Network:https://clinicaltrials.gov/ct2/show/NCT04647227
3MASAC Document 263 - MASAC Recommendations Concerning Products Licensed for the Treatment of Hemophilia and Other Bleeding Disorders (Revised August 2020). National Hemophilia Foundation. Available at: https://www.hemophilia.org/sites/default/files/document/files/263_treatment.pdflast accessed on February 7, 2020.
Didier Véron - Executive VP Corporate Affairs
Tel: +33 (0)188.8.131.52.97 or +33 (0)6.08.56.76.54
HEMA Biologics Contacts (US):
Chris Macie, Senior Director, Medical Affairs
Cell number: (+1) 770-331-5761 - email@example.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Introduces PixCell LED for Intelligent Headlight Systems to Enhance Road Safety15.4.2021 10:10:00 CEST | Press release
Samsung Electronics Co., Ltd., a world leader in advanced digital component solutions, today announced PixCell LED, a new automotive LED module optimized for intelligent headlights, such as adaptive driving beam (ADB) systems. ADB headlamps powered by Samsung’s PixCell LEDs will help improve driver visibility and safety to enhance the overall driving experience at night and in poor weather conditions such as fog or heavy rain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210415005407/en/ Samsung Introduces PixCell LED for Intelligent Headlight Systems to Enhance Road Safety (Graphic: Business Wire) “Much more than a simple automotive lighting source, Samsung’s PixCell LED is based on new lighting technology designed to improve road safety and driving convenience,” said Un Soo Kim, senior vice president of the LED Business Team at Samsung Electronics. “Beginning with PixCell LED, we will introduce tailored lighting solution
New F1 Insights Powered by AWS Will Help FORMULA 1 Fans Make Sense of Split-Second Decisions on the Track15.4.2021 09:30:00 CEST | Press release
Today, Amazon Web Services (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN), and FORMULA 1 (F1) (NASDAQ: FWONA, FWONK) are introducing six new F1 Insights powered by AWS that will roll out through the 2021 racing season. The new additions mean a total of 18 AWS-powered stats will be available to fans by the end of the season. F1 Insights powered by AWS are real-time racing statistics, displayed as on-screen graphics, that transform the fan experience before, during, and after each race by providing the data and analysis fans need to interpret driver and team race strategy and performance. The first new stat, Braking Performance, will debut at the GRAND PRIX in Italy, April 16-18. The new set of statistics for 2021 will use a range of AWS technologies, including machine learning, to help fans better understand and highlight potential race outcomes and compare their favorite drivers and cars.For more information about AWS and its involvement with F1, including the 12 previously released
Peter Windisch Appointed Chief Technology Officer at Excelya15.4.2021 09:03:00 CEST | Press release
Today, Excelya, the leading European contract research organization, has announced the appointment of Peter Windisch to the position of Chief Technology Officer (CTO). As CTO, Peter will aim to leverage data and technology to further optimize its client offer. He will be made a member of the Executive Committee and will be based in Germany. Peter was most recently VP of Operations and Client Partner at PRA Health Sciences and has worked for decades in various leadership positions in health and technology. He began his career in health as a Manager of Information Technology and Data Management before moving up the ranks to Managing Director of various regions in Europe at IMEREM (now part of PRA Health Sciences) and ReSearch Pharmaceutical Services. Alan Morgan, CEO of Excelya: “Excelya is investing heavily in technology to better support our clients and patients for the trials that we are managing. Innovation and efficiency are at the heart of what we do. This new position recognizes t
Completion of the Third Clinical Trial - an Important Achievement for Medicortex Finland15.4.2021 08:25:00 CEST | Press release
Medicortex Finland Oy, a biotechnology company developing a breakthrough biomarker-based diagnostic kit for brain injury detection, completed collection of body fluid samples in its third large clinical study. Children and adolescents were recruited who visited the hospital with a suspected mild traumatic brain injury or concussion. "Collecting the samples in this large clinical trial is a significant achievement for Medicortex, and represents an important step forward in the development of the ProbTBITM, a diagnostic kit for early detection of head injury" said Dr. Adrian Harel, Chief Executive Officer of Medicortex Finland. "Brain injury is a devastating condition leading to medical complications if not diagnosed. We have the opportunity to develop a portable non-invasive test for quick detection of mild traumatic brain injury (TBI) and concussion, and thereby help young patients and families who so desperately need it.” Dr. Harel added. In the current clinical study Medicortex colle
Valbiotis: Largely Successful Capital Increase Through a Private Placement Totaling 15 Million Euros15.4.2021 07:35:00 CEST | Press release
Regulatory News: Valbiotis (Paris:ALVAL) (FR0013254851 – ALVAL, PEA-PME eligible), a Research & Development company committed to scientific innovation for the treatment and prevention of metabolic diseases, today announces the large successful capital increase through a private placement open to certain categories of beneficiaries launched the previous day and achieved using an accelerated bookbuilding process. Given the very high demand from French and international investors, Valbiotis decided to set the amount of the capital increase at 15 million euros, compared to approximately 12 million euros initially forecast. Sébastien PELTIER, CEO of Valbiotis stated: "I am extremely grateful to all the new investors who participated in this capital increase, as well as all our historic shareholders who continue to support our company in its mission and its development. This capital increase is key, as it will enable us to accelerate our development program for the prevention of high blood p
ABB Issues Trading Update Following Better-Than-Anticipated Performance in Q115.4.2021 06:46:00 CEST | Press release
ABB is publishing preliminary information on its first-quarter 2021 results, which according to the information available to the company, is better than the latest company guidance and current market consensus. The preliminary results were driven by a stronger-than-anticipated market development, especially during the last weeks of March, and relates primarily to the short-cycle business. Quarterly demand is likely to have been supported by customer stock-building activities related to both component availability constraints and rising commodity prices in the industry. Preliminary results for first quarter 2021: ($ millions, unless otherwise indicated) Change Q1 2021 Q1 2020 US$ Comparable1 Orders ~7,750 7,346 ~+6% ~+1% Revenues ~6,900 6,216 ~+11% ~+7% Operational EBITA2, % ~13.5% 10.2% ~+330 pts On the back of recent market developments, ABB is raising its revenue guidance for full year 2021 outlook and now anticipates comparable revenue growth of ~5% or higher (previously: comparable
Mattel Unveils First-of-its-Kind, CarbonNeutral ® Matchbox ® Tesla Roadster Die-cast Vehicle Made from 99% Recycled Materials to Serve as Brand Blueprint15.4.2021 06:01:00 CEST | Press release
Today, Mattel, Inc. (NASDAQ: MAT) announced Drive Toward a Better Future, its product roadmap to make all Matchbox die-cast cars, playsets and packaging with 100% recycled, recyclable or bio-based plastic by 2030. This is in line with Mattel’s goal to achieve 100% recycled, recyclable or bio-based plastic materials across all its products and packaging by 2030. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210414006005/en/ Mattel is unveiling the Matchbox Tesla Roadster, its first die-cast vehicle made from 99% recycled materials and certified CarbonNeutral®*. The Matchbox Tesla Roadster will be available starting in 2022. (Photo: Business Wire) To illustrate these principles, Mattel is unveiling the Matchbox TeslaRoadster, its first die-cast vehicle made from 99% recycled materials and certified CarbonNeutral®*. The Matchbox Tesla Roadster will be available starting in 2022. The reimagined broader Matchbox brand includes n
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom